Prelude Therapeutics, Inc. PRLD 深 沪
等待开盘 07-08 09:30:00 美东时间
4.9701
-0.020
-0.40%
华盛通- 最 高5.055
- 今 开4.96
- 成交量 15.78万股
- 最 低 4.65
- 昨 收 4.99
- 总市值 3.96亿
- 52周最高 5.69
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.75
- 委 比 -55.91%
- 总股本 7964.53万
- 历史最高 95.375
- 量 比 0.51
- 振 幅 8.12%
- 历史最低 0.6101
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics announced the appointment of Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee. Both bring extensive experience in biotechnology leadership. Babler previously led Alumis Inc., Principia Biopharma Inc., and Talima Therapeutics, Inc., while Cox served as CEO of Foundation...
06-24 11:00
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Dave and Buster’s Entertainment, Inc (NASDAQ:PLAY) fell sharply in pre-market trading as the company reported downbeat earnings for the first quarter. The company posted quarterly earnings of ...
06-16 20:05
Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.25) by 48 percent. This is a 69.05 percent increase over losses of $(0.42) per share from
05-12 19:46
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9
D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Buy rating and announces Price Target of $9.
05-04 21:58
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
Prelude Therapeutics, Inc. ($PRLD) announced an update on their ongoing clinica...
05-03 00:30
美股夜盘 | Prelude Therapeutics, Inc.涨21.78%，最新股价5.2美元
Prelude Therapeutics, Inc.涨21.78%，报5.2美元
05-01 08:21
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.
04-27 20:40
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.
04-27 19:57
